Navigation Links
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
Date:6/10/2009

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.

The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously not on pharmacological therapy showed a dose dependent decrease in fasting plasma glucose (FPG) at 4 weeks, the primary endpoint of the study. This decrease was already statistically significant at 1 week for both low and high doses (1 mg and 10 mg) of INT131.

The efficacy measured at 4 weeks of 1 mg of INT131 treatment was comparable to the efficacy modeled for this patient population treated with the maximal approved doses of Actos(R) and Avandia(R), but in contrast the low dose INT131 group did not show the significant weight gain or fluid retention (measured by hematocrit drop) modeled for maximal dose TZDs. The high dose INT131 group showed about twice the decrease in FPG attained with low dose INT131, and a correspondingly greater efficacy compared to that modeled for maximal dose TZDs. Importantly, this greater efficacy was achieved with INT131 without greater weight gain or hematocrit drop than expected for maximal dose TZDs. INT131 was well tolerated in this study with no safety issues noted.

"These data are supportive of INT131 acting as a selective modulator of PPARgamma in T2DM patients," remarked Dr Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, who presented the data. "The key observation from this study is that INT131 is a potent insulin sensitizer that lowers fasting glucose as well as the maximal dose of the TZDs while mitigating the typical side effect profile."

"Transla
'/>"/>

SOURCE InteKrin Therapeutics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. InteKrin Therapeutics Announces $20 Million Series C Financing
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
8. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
9. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
10. Cephalon Acquires Controlling Interest in Arana Therapeutics
11. Cornerstone Therapeutics Announces Management Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 Barbara Crone ... worked to enhance the well being of the men, women and ... a hospital, followed by providing care for families in the home. ... an Adult Nurse Practitioner began wondering if I could complete their ... of my own children with my mentor Nurse Midwife, I knew ...
(Date:5/3/2015)... Bubbly Walrus ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... to play on smartphones are the ones that get users ... a video game that just absorbs attention, why not exercise ...
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
(Date:5/2/2015)... 2015 As one of only 30 ... Safety and Health Achievement and Recognition Program (SHARP) certification, ... chosen by the Illinois Department of Labor to host ... maintained SHARP certification by the Occupational Safety and Health ... has continued to meet or exceed all of the ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3
... Inc. told the National Heritage Insurance Co., the contractor that ... to cover its test. ,After this the company’s ... to $12.41 on Nasdaq. The company prepares oncotype DX breast ... taking all the responsibility to cover the medical expenses related ...
... virus has been steadily increasing, with more// than 50 ... in other parts of the territory. // Furthermore, reports of ... past three weeks has prompted reasons for concern among the ... occurred has been one that hit Darwin a decade ago ...
... time from six weeks to five days. This is very useful ... can point the radiation source at the tumor killing the cancer ... therapy over the conventional six-week treatment. They are also in the ... ,But the Canadians are working on a new therapy for breast ...
... Scientist working at the DeCode Genetics Inc (Reykjavik company) was ... the diabetic population in US. ,The Icelandic ... is not known, but is thought to regulate the genes ... in the Icelandic population, as they are a close nit ...
... Pathology, University of Michigan Medical School has reported in ... for producing hypersensitive immune response leading to autoimmune disease. ... the bacteria against which the protein produces an immune ... the immune system to produce an immune response against ...
... the fourth largest reservoir of scientific and research talent ... is poised to emerge as the preferred hub for ... knowledge economy are not restricted to information and communication ... biotech, nanotechnology, missile technology and space. ,India's ...
Cached Medicine News:Health News:Western Australia Witnesses Rise In Ross River Virus Infection 2Health News:Gene Linked To Type 2 Diabetes Identified 2Health News:India set to become the global knowledge hub 2Health News:India set to become the global knowledge hub 3Health News:India set to become the global knowledge hub 4
(Date:5/1/2015)... May 1, 2015  CytRx Corporation (CYTR), a ... today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its ... milestones in the early months of 2015, including ... trial of aldoxorubicin in patients with soft tissue ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26
... Greenway Medical Technologies, Inc. and the Physician ... (INHS) today announced an agreement for INHS to ... practice management solution PrimeSUITE® 2011 to ... coordination and network interoperability. Established more ...
... Cohera Medical, Inc.®, a rapidly growing medical device company, ... for its lead product, TissuGlu® Surgical Adhesive. ... sold in the European Union. TissuGlu ... surgeries, such as abdominoplasties, that helps reduce fluid accumulation ...
Cached Medicine Technology:Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
Insert only, Ethicon medium-large clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: